Commentary (Thomas/Greco): Myalgias and Arthralgias Associated With Paclitaxel

Despite nearly a decade of paclitaxel’s commercial availability, the best strategy for managing several paclitaxel-related toxicities including myalgia/arthralgia remains to be elucidated. Most available data in the treatment of myalgia/ arthralgia have been anecdotal, reported in the form of case studies or within the toxicity results of published paclitaxel-containing clinical trials. Garrison et al have provided a well-written review summarizing what is currently known about the incidence and management of this quality-of-life–impacting toxicity.